Investigators have presented full results from a late-stage study which sheds more light on Sanofi's decision to halt development of its injectable factor Xa inhibitor otamixaban. - News - PharmaTimes
by Ian Mason
www.pharmatimes.com/news/more_details_on_failure_of_sanofis_otamixaban_at_esc_1005624Having had no new drugs for hepatitis C since ribavirin’s approval more than a decade ago, doctors will shortly be spoilt for choice. - News - PharmaTimes
by Ian Mason in Berlin
www.pharmatimes.com/news/avalanche_of_hepatitis_c_products_on_the_way_979325Ahead of the eagerly-awaited American Society of Clinical Oncology event being held next month in Chicago, a pre-meeting briefing included studies showing that maintenance therapy with Roche/Biogen Idec’s Rituxan halves risk of lymphoma recurrence,
by Ian Mason
www.pharmatimes.com/news/asco_build-up_begins,_promising_rituxan_and_revlimid_data_983196Boehringer Ingelheim says that data, due to be presented at the American Society of Clinical Oncology meeting in a couple of weeks, shows that the company’s BIBW 2992 shrank tumours in 22% of patients with head and neck cancer (measured as partial
by Ian Mason
www.pharmatimes.com/news/boehringer_drug_as_effective_as_erbitux_in_head-and-neck_cancer_983185Daiichi Sankyo's once-daily oral factor Xa inhibitor edoxaban is as effective as warfarin with a better safety profile when used for preventing recurrence of acute venous thromboembolism, according to results from the Phase III Hokusai-VTE trial
by Ian Mason
www.pharmatimes.com/news/daiichi_sankyos_edoxaban_will_shake_things_up_1005618
